Cargando…

Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma

With 15 drugs currently approved for the treatment of metastatic renal cell carcinoma (mRCC) and even more combination regimens with immunotherapy on the horizon, there remains a distinct lack of molecular biomarkers for therapeutic efficacy. Our study reports on real-world clinical outcomes of mRCC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Viola J., Hernandez-Meza, Gabriela, Agrawal, Prashasti, Zhang, Chiyuan A., Xie, Lijia, Gong, Cynthia L., Hoerner, Christian R., Srinivas, Sandy, Oermann, Eric K., Fan, Alice C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678132/ https://www.ncbi.nlm.nih.gov/pubmed/31319594 http://dx.doi.org/10.3390/cancers11071000

Ejemplares similares

The ‘Achilles Heel’ of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy
por: Hoerner, Christian R., et al.
Publicado: (2019)

LHC Re-Opening Delayed at Least Two Months
Publicado: (2009)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinoma
por: Barkan, Ella, et al.
Publicado: (2023)

An Emerging Paradigm for Psychiatric Practice in Integrated Care Amidst a Crisis
por: Saxena, Parnika Prashasti
Publicado: (2020)

T cell perturbations persist for at least 6 months following hospitalization for COVID-19
por: Govender, Melissa, et al.
Publicado: (2022)

Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis
por: Zhong, Lixian, et al.
Publicado: (2013)

The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
por: Castro, Daniela, et al.
Publicado: (2023)

Clinicomicrobiological study of community-acquired pneumonia
por: Prasad, Prashasti, et al.
Publicado: (2017)

Development and validation of a nomogram to predict overall survival for patients with metastatic renal cell carcinoma
por: Zheng, Wenwen, et al.
Publicado: (2020)

The Gut Microbiome and Metastatic Renal Cell Carcinoma
por: Meza, Luis, et al.
Publicado: (2023)

Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer
por: Goldstein, David, et al.
Publicado: (2020)

In silico identification and molecular dynamic simulations of derivatives of 6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide against main protease 3CL(pro) of SARS-CoV-2 viral infection
por: Sinha, Prashasti, et al.
Publicado: (2023)

Partial least squares based gene expression analysis in renal failure
por: Ding, Shuang, et al.
Publicado: (2014)

Multidisciplinary Team (MDT) Discussion Improves Overall Survival Outcomes for Metastatic Renal Cell Carcinoma Patients
por: Zeng, Yuhao, et al.
Publicado: (2023)

The bevacizumab experience in advanced renal cell carcinoma
por: Harshman, Lauren C, et al.
Publicado: (2010)

The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma
por: Swallow, Elyse, et al.
Publicado: (2018)

Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy
por: Pivot, X., et al.
Publicado: (2016)

Persistent COVID-19 symptoms at least one month after diagnosis: A national survey
por: Tleyjeh, Imad M., et al.
Publicado: (2022)

Clinical Approach to Recurrent Voiding Dysfunction, Dysuria, and Pelvic Pain Persisting for at Least 3 Months
por: Kim, Su Jin, et al.
Publicado: (2022)

Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
por: Waliany, Sarah, et al.
Publicado: (2019)

Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma
por: Gu, Weijie, et al.
Publicado: (2015)

Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post‐vaccination but persist for at least 6 months
por: Mordant, Francesca L., et al.
Publicado: (2022)

Fast Algorithms for Structured Least Squares and Total Least Squares Problems
por: Kalsi, Anoop, et al.
Publicado: (2006)

A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study
por: Corino, Valentina D. A., et al.
Publicado: (2021)

IgG SARS-CoV-2 Antibodies Persist at Least for 10 Months in Patients on Hemodialysis
por: Dudreuilh, Caroline, et al.
Publicado: (2021)

SARS-CoV-2 remains infectious for at least a month on artificially-contaminated frozen berries
por: Esseili, Malak A., et al.
Publicado: (2022)

Sustainable power generation for at least one month from ambient humidity using unique nanofluidic diode
por: Zhang, Yong, et al.
Publicado: (2022)

Physical Therapy for at Least 6 Months Improves Motor Symptoms in Parkinson's Patients: A Meta-Analysis
por: Ji, Xiaotian, et al.
Publicado: (2022)

Characterizing the outcomes of metastatic papillary renal cell carcinoma
por: Connor Wells, John, et al.
Publicado: (2017)

The Path of Least Resistance
por: Jalli, Sandeep S., et al.
Publicado: (2021)

The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma
por: AKTEPE1, Oktay Halit, et al.
Publicado: (2021)

Live bacterial supplementation for improving treatment response in metastatic renal cell carcinoma
por: Meza, Luis, et al.
Publicado: (2022)

A low-barrier hydrogen bond mediates antibiotic resistance in a noncanonical catalytic triad
por: Kumar, Prashasti, et al.
Publicado: (2018)

Late Brain Oligometastases Diagnosed at Least 36 Months after Cancer Detection are Associated with Favorable Survival Outcome
por: Nieder, Carsten, et al.
Publicado: (2020)

The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients
por: Levi, Riccardo, et al.
Publicado: (2021)

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Previous omicron infection may be protective against reinfection with omicron variant BA.5 for at least 5 months
por: Koga, Michiko, et al.
Publicado: (2023)

SARS-CoV-2 RNA Is Readily Detectable at Least 8 Months after Shedding in an Isolation Facility
por: Coil, David A., et al.
Publicado: (2022)

Factors Associated With Initiating Breastfeeding and Continuing it for At Least 4 Months in Consuelo, a Rural Town in the Dominican Republic
por: Bhuyan, Anjalee, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kvf3d35efa86nrm71j8qtvp9ak